Genitourinary Cancer

EDU 18 - How to Incorporate Commercial Genomic Tests into Your Management of Prostate Cancer: Evidence and Limitations

9/17/2019
2:45 PM - 4:00 PM
Location: Room W181

Session Type: Education
1.25 AMA PRA Category 1 Credits™
1.25 CAMPEP Credits
1.50 MDCB Credits

Patients with prostate cancer are increasingly utilizing commercially available genomic tests (Prolaris, Oncotype DX, Decipher, etc.) to further risk stratify their cancer prior to proceeding with treatment. As we move further towards personalized/precision medicine, we must understand the potential added-value as well as limitations of the genomic tests, and how to incorporate them into clinical practice. As prostate cancer becomes increasingly multi-disciplinary, radiation oncologists must have a firm grasp of what these tests can and cannot provide so as to assist the patient and the peer urology/medical oncology team in medical decision-making. In this session, we will review the clinical evidence behind each of the commercially available genomic tests with an emphasis on what the tests can and cannot predict, and go through sample cases with a panel of experts to see how these tests may influence clinical management.

Learning Objectives:

Presentations:

Jing Zeng, MD

University of Washington

Disclosure:
Employment
University of Washington: Associate Professor: Employee

Presentation(s):

Send Email for Jing Zeng


Assets

EDU 18 - How to Incorporate Commercial Genomic Tests into Your Management of Prostate Cancer: Evidence and Limitations



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for EDU 18 - How to Incorporate Commercial Genomic Tests into Your Management of Prostate Cancer: Evidence and Limitations